文献速递瓣膜病与结构性心脏病

经导管主动脉瓣植入中全麻与局麻联合清醒镇静的随机对照试验:SOLVE-TAVI研究

General Versus Local Anesthesia With Conscious Sedation in Transcatheter Aortic Valve Implantation: The Randomized SOLVE-TAVI Trial.
PubMed 文献 · Circulation · 2020-08-21

SOLVE-TAVI试验为多中心、开放标签、2×2析因随机研究,纳入447例经股动脉TAVR的重度主动脉瓣狭窄患者,比较清醒镇静(CS)与全身麻醉(GA)。主要复合疗效终点(全因死亡、卒中、心梗、需抗生素治疗的感染、急性肾损伤)30天发生率CS组27.2%、GA组26.4%,率差0.8%(90%CI -6.2~7.8),达到等效性(P=0.015)。结论提示CS可安全用于TAVR。

要点

  • CS与GA在30天主要复合终点达到等效性(率差0.8%,90%CI -6.2~7.8)。
  • CS组需要正性肌力药或血管升压药的比例显著低于GA组(62.8% vs 97.3%)。
  • 各单项终点事件率组间差异均无统计学意义,且均达到等效性。

核心结论

  • 在经股动脉TAVR的主动脉瓣狭窄患者中,CS与GA相比主要复合疗效终点结局相似,CS可安全应用。

研究设计与样本

  • SOLVE-TAVI为多中心、开放标签、2×2析因随机试验,共纳入447例接受经股动脉TAVR的主动脉瓣狭窄患者,比较CS与GA。

主要发现

  • 30天主要复合终点(全因死亡、卒中、心梗、需抗生素治疗的感染、急性肾损伤)发生率CS组27.2%、GA组26.4%,率差0.8%(90%CI -6.2~7.8),P等效性=0.015。
  • 全因死亡率CS组3.2%、GA组2.3%(率差1.0%,90%CI -2.9~4.8,P等效性<0.001)。
  • 卒中发生率CS组2.4%、GA组2.8%(率差-0.4%,90%CI -3.8~3.8,P等效性<0.001)。
  • 需抗生素治疗的感染发生率CS组21.1%、GA组22.0%(率差-0.9%,90%CI -7.5~5.7,P等效性=0.011)。
  • 急性肾损伤发生率CS组9.0%、GA组9.2%(率差-0.2%,90%CI -5.2~4.8,P等效性=0.0005)。

关键数值与推荐

  • 主要疗效终点等效性界值为10%,显著性水平0.05。
  • CS组需要正性肌力药或血管升压药的比例为62.8%,GA组为97.3%,率差-34.4%(90%CI -41.0~-27.8)。

临床怎么用

  • 对于经股动脉TAVR的主动脉瓣狭窄患者,CS可作为GA的替代麻醉策略,且不增加30天主要不良事件风险。
  • CS可能减少术中正性肌力药或血管升压药的使用需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In clinical practice, local anesthesia with conscious sedation (CS) is performed in roughly 50% of patients undergoing transcatheter aortic valve replacement. However, no randomized data assessing the safety and efficacy of CS versus general anesthesia (GA) are available. METHODS: The SOLVE-TAVI (Comparison of Second-Generation Self-Expandable Versus Balloon-Expandable Valves and General Versus Local Anesthesia in Transcatheter Aortic Valve Implantation) trial is a multicenter, open-label, 2×2 factorial, randomized trial of 447 patients with aortic stenosis undergoing transfemoral transcatheter aortic valve replacement comparing CS versus GA. The primary efficacy end point was powered for equivalence (equivalence margin 10% with significance level 0.05) and consisted of the composite of all-cause mortality, stroke, myocardial infarction, infection requiring antibiotic treatment, and acute kidney injury at 30 days. RESULTS: The primary composite end point occurred in 27.2% of CS and 26.4% of GA patients (rate difference, 0.8 [90% CI, -6.2 to 7.8]; Pequivalence=0.015). Event rates for the individual components were as follows: all-cause mortality, 3.2% versus 2.3% (rate difference, 1.0 [90% CI, -2.9 to 4.8]; Pequivalence<0.001); stroke, 2.4% versus 2.8% (rate difference, -0.4 [90% CI, -3.8 to 3.8]; Pequivalence<0.001); myocardial infarction, 0.5% versus 0.0% (rate difference, 0.5 [90% CI, -3.0 to 3.9]; Pequivalence<0.001), infection requiring antibiotics 21.1% versus 22.0% (rate difference, -0.9 [90% CI, -7.5 to 5.7]; Pequivalence=0.011); acute kidney injury, 9.0% versus 9.2% (rate difference, -0.2 [90% CI, -5.2 to 4.8]; Pequivalence=0.0005). There was a lower need for inotropes or vasopressors with CS (62.8%) versus GA (97.3%; rate difference, -34.4 [90% CI, -41.0 to -27.8]). CONCLUSIONS: Among patients with aortic stenosis undergoing transfemoral transcatheter aortic valve replacement, use of CS compared with GA resulted in similar outcomes for the primary efficacy end point. These findings suggest that CS can be safely applied for transcatheter aortic valve replacement. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02737150.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Thiele H, Kurz T, Feistritzer HJ, et al. General Versus Local Anesthesia With Conscious Sedation in Transcatheter Aortic Valve Implantation: The Randomized SOLVE-TAVI Trial. Circulation. 2020. PMID: 32819145. doi:10.1161/CIRCULATIONAHA.120.046451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。